Lung cancer biomarkers: present status and future developments
PT Cagle, TC Allen, RJ Olsen - Archives of Pathology …, 2013 - meridian.allenpress.com
The publication of the “Molecular Testing Guideline for Selection of Lung Cancer Patients for
EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …
EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis
CJ Ensslin, AC Rosen, S Wu, ME Lacouture - Journal of the American …, 2013 - Elsevier
Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …
therapies. The risk of pruritus has not been systematically ascertained. Objective A …
[HTML][HTML] Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
Background: EGFR and KRAS mutations are mutually exclusive and predict outcomes with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …
[HTML][HTML] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
YY Janjigian, BJ Park, MF Zakowski, M Ladanyi… - Journal of Thoracic …, 2011 - Elsevier
Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis
BC Garden, S Wu, ME Lacouture - Journal of the American Academy of …, 2012 - Elsevier
BACKGROUND: The overall incidence and risk of nail changes associated with the use of
epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature …
epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature …
Incidence and risk of xerosis with targeted anticancer therapies
J Valentine, VR Belum, J Duran, K Ciccolini… - Journal of the American …, 2015 - Elsevier
Background Many targeted therapies used in the treatment of cancer can lead to the
development of xerosis, but the incidence and relative risk of xerosis have not been …
development of xerosis, but the incidence and relative risk of xerosis have not been …
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA‐4
A Fischer, AC Rosen, CJ Ensslin, S Wu… - Dermatologic …, 2013 - Wiley Online Library
In the past decade, the expanded use of targeted anticancer drugs has significantly
prolonged survival in patients treated for a variety of cancers. Despite their increased …
prolonged survival in patients treated for a variety of cancers. Despite their increased …
[PDF][PDF] Таргетная терапия местно-распространенного немелкоклеточного рака легкого с EGFR-мутацией
ЮА Рагулин, ЕИ Смоленов, ВС Усачев… - … . Журнал им. ПА …, 2016 - researchgate.net
Обобщены сведения о применении таргетной терапии ингибиторами EGFR в
неоадъювантном и адъювантном режимах при лечении немелкоклеточного рака …
неоадъювантном и адъювантном режимах при лечении немелкоклеточного рака …
[HTML][HTML] Lung Cancer Biomarkers: Present Status and Future Developments [Archives of Pathology & Laboratory Medicine]
RJ Olsen - Arch Pathol Lab Med, 2013 - insurancenewsnet.com
* The publication of the" Molecular Testing Guideline for Selection of Lung Cancer Patients
for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …
for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …